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ABSTRACT
Major Depressive Disorder (MDD) in gynaecological cancer patients is a disabling illness with 
signifi cant mental and physical suffering. Determining the risk factors of MDD in cancer patients enables 
us to pay more attention to those who are vulnerable and to device effective strategies for prevention, 
early detection, and treatment. The objective of the study is to determine the prevalence of MDD and 
its associated risk factors in gynaecological cancer patients at Hospital Sultanah Bahiyah, Alor Star. 
This is a hospital-based cross-sectional descriptive study of 120 gynaecological cancer patients in 
Gynae-Oncology Unit in Hospital Sultanah Bahiyah, Alor Star. Mini International Neuropsychiatry 
Interview (MINI) was used for diagnosis of MDD. Socio-demographic data and clinical variables 
were collected. MVFSFI (Malay version Female Sexual Function Index) was used to determine sexual 
dysfunction, and WHOQOL-BREF (World Health Organization – Quality of Life-26) was performed 
to assess quality of life. The prevalence of MDD in gynaecological cancer patients in the study was 
18%. The variables found to be signifi cantly associated with MDD were lack of perceived social 
support, greater physical pain perception, presence of past psychiatric history, and poorer quality 
of life. Meanwhile, sexual dysfunction was not associated with MDD. Logistic regression analysis 
revealed that only the psychological health domain of QOL was signifi cantly associated with MDD, 
and contributed to 60% of the variation in MDD. The prevalence of MDD in gynaecological cancer 
patients is higher than those in the general population. In view that MDD can compromise cancer 
prognosis and patient’s well-being, psychosocial intervention is recommended as a part of multi-
disciplinary and comprehensive management of gynaecological cancer.
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INTRODUCTION
According to the Planning and Development Division of the Ministry of Health Malaysia (2003), cancer is the 
second leading cause of death in Malaysia. Each year, it is estimated that approximately 30 000 new cases of 
cancer are being diagnosed[1]. In Malaysia, the most common gynaecological cancer is cervical cancer, followed 
by ovarian cancer. The National Cancer Registry (2003) showed that over 1 500 women developed cervical cancer, 
and 700 died of it every year in Peninsular Malaysia. Yet, cervical cancer is also the most preventable cancer today. 
According to the same registry, ovarian cancer is the fourth most common cancer among women in Peninsular 
Malaysia, contributing to 5% of all female cancer cases[1].
In Malaysia, the third National Health and Morbidity Survey (NHMS III 2006) reported that the overall 
estimated prevalence of recent psychiatric morbidity was 11.2%. However, among those with cancer and chronic 
pain, the psychiatric morbidity was much higher, with 67% and 64%, respectively[2]. Worldwide, among patients 
with general cancer, 30%-60% of them had a psychiatric diagnosis dependent on the types of cancer, age group 
of the patients, countries and other factors[3, 4, 5, 6, 7]. In a local study among 168 cancer patients undergoing 
chemotherapy, the prevalence of anxiety/depression (Hospital Anxiety & Depression Scale – HADS) was 32% [8]. 
Cancer patients had 14 times increased risk of getting a psychiatric diagnosis[6]. It was concluded that nearly 90% 
of the psychiatric disorders observed were either reactions to, or parts of disease and treatment manifestations[4, 8]. 
There is a broad spectrum of emotional disturbance, ranging from normal reactive sadness to MDD[9].
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MDD is a medical illness characterized by persistent low mood, loss of interest and socio-occupational 
impairment. In overseas studies, the prevalence of MDD in gynaecological cancer was found to be between 12% 
- 23%[4, 10, 12, 13]. The prevalence of MDD was infl uenced by multiple risk factors, ranging from patients’ clinical, 
psycho-sexual and quality of life variables. Known risk factors are poor social support, low education level, low 
income, chemotherapy or radiotherapy and physical pain[8, 9, 10, 11, 13]. When clinical depression is present, it may 
hamper treatment decision-making, impede recovery, and increase mortality[11]. Depression in cancer patients can 
also affect their relationships with their loved ones, productivity at work place, quality of life, and lead to higher 
suicide rates[14, 15, 16, 17].
The objective of this study was to determine the prevalence of MDD and its associated risk factors (socio-
demographic, clinical, sexual dysfunction, and quality of life) in gynaecological cancer patients at Hospital 
Sultanah Bahiyah, Alor Star. It has implications on identifying those who are at risk of depression for psychosocial 
intervention. This study will contribute to a more comprehensive management of gynaecological cancer, thus, 
improving prognosis and quality of life in patient care.
MATERIALS AND METHODS 
This is a hospital-based cross-sectional descriptive study of 120 gynaecological cancer patients in Gynae-Oncology 
Unit at Hospital Sultanah Bahiyah, Alor Star. A calculated sample size of around 109 patients was required to 
obtain a 95% CI of ± 5% around a depression prevalence estimate of 20%. The sample comprised of patients 
diagnosed with gynaecological cancer and were receiving various outpatient and inpatient services (chemotherapy, 
radiotherapy, surgery) over a consecutive period of fi ve months. Non-probability sampling method was used; the 
investigator travelled to the hospital for data collection twice a week. The eligibility criteria were of 18 years or 
older, able to communicate effectively and to give informed consent. Meanwhile, the exclusion criteria included 
patients with history of drug abuse and signifi cant cognitive impairment, and those who refused to give consent 
and were unable to communicate. The study was approved by the Department of Psychiatry and Medical Research 
Ethical Committee of Universiti Kebangsaan Malaysia Medical Centre (UKMMC), and registered with the National 
Medical Research Registry (NMRR).
Subjects were interviewed using questionnaires that included socio-demographic variables (i.e., age, ethnicity, 
religion, religious practice, marital status, occupation, education level, husband’s help in the household, presence 
of husband and children less than 18 years old at home, perceived social support), and clinical variables (i.e., 
type of cancer, duration of illness, staging, metastasis, recurrence, cancer treatment modalities, pain perception, 
medical illness and treatment, and history of psychiatric illness). Three other questionnaires used were: 1. Mini 
International Neuropsychiatry Interview (MINI), 2. Malay version of World Health Organization Quality of Life 
(WHOQOL-BREF), and 3. Malay Version Sexual Female Sexual Function Index (MVFSFI).
Mini International Neuropsychiatric Interview (MINI) was developed by Sheehan and Lecrubier[18], and used 
for establishing the diagnosis of MDD in this study. It can be used by clinicians after a brief training session. In 
particular, MINI was designed to be a brief structured interview for Axis I diagnosis of major psychiatric disorders 
in Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), and International Classifi cation of Disease 
(ICD-10). Some studies have been done to compare MINI with Structured Clinical Interview for DSM-III-R (SCID) 
and Composite International Interview (CIDI), and shown to have acceptable validity and reliability.
The Malay version of World Health Organization Quality of Life (WHOQOL-BREF) was used to determine 
quality of life. It is a 26-item self-report questionnaire that allows detailed assessment of each individual’s aspects 
relating to quality of life: physical, psychological, social and environment[19]. Higher scores indicate better quality 
of life. Internal consistency (Cronbach alphas, 0.66 – 0.84) and test-retest reliability (0.66 – 0.87) were found to 
be good for each of the four domains. Factor analysis confi rmed the comparative fi t of the four domain model 
of global quality of life. The Malay version of WHOQOL-BREF had been validated in the local population, and 
used previously in other studies[20].
Meanwhile, the Malay Version Sexual Female Sexual Function Index (MVFSFI) was used to determine sexual 
dysfunction[21]. In MVFSFI, the cut-off total score for sexual dysfunction was ≤ 55 and the cut-off score for each 
domain of sexual dysfunctions was as follows: ≤ 5 for the sexual desire disorder (sensitivity 95% and specifi city 
89%); ≤ 9 for sexual arousal disorder (sensitivity 77% and specifi city 95%); ≤ 10 for disorder of lubrication 
(sensitivity 79% and specifi city 87%); ≤ 4 for orgasmic disorder (sensitivity 83% and specifi city 85%); ≤ 11 for 
sexual dissatisfaction (sensitivity 83% and specifi city 85%); and ≤ 7 for sexual pain disorder (sensitivity 86% and 
specifi city 95%).
All data were analyzed using the Statistical Package for Social Sciences (SPSS) version 11.5. Initially, 
associations between socio-demographic, clinical and other variables, and MDD were tested. For categorical 
data (e.g. gender), Chi-square test was used. Student T-Test was used to analyze normally distributed quantitative 
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variables (i.e., only age). As for not normally distributed quantitative variables (e.g., cancer duration), Mann-
Whitney U test was used. Later, binary logistic regression test was used to analyze the association between those 
variables that were signifi cantly associated with MDD. The level of statistical signifi cance was set at p < .05. 
Post-hoc analysis using power analysis and sample size calculation software, “G*Power 3” (http://www.psycho.
uni-duesseldorf.de/abteilungen/aap/gpower3/) [22], the power of the study for all the variables were at least 80% 
(α = 0.05, medium effect size, two-tailed test), except for the variables ‘age’ and ‘duration of cancer’ (power > 
80% only if effect size is large).
RESULTS
In this study, the age of the cancer patients ranged from 20 to 74 years old. The mean age was 50. 60 years old 
(SD ± 11.50 years). More than forth-fi fth of the subjects (99, 82%) were more than 40 years old. Other socio-
demographic data of the patients are presented in Table 1.
Table 1. Socio-demographic data of gynaecological cancer patients
  Count (N =120)    Percentage (%)
Ethnic Malay 75 63%
 Chinese 28 23%
 Indian 12 10%
 Others 5 4%
Religion Islam 77 64%
 Buddhism 29 24%
 Christianity 5 4%
 Hinduism 9 8%
Religious practice Frequent 95 79%
 Occasional 20 17%
 No 5 4%
Marital status Married 83 69%
 Single 14 12%
 Divorced/Separated 7 6%
 Widowed 16 13%
Education level No formal 13 11%
 Primary 31 26%
 Secondary 56 46%
 Tertiary 20 17%
Employment before  Employed 68 57%
cancer diagnosis Unemployed 52 43% 
Employment after  Employed 22 98
cancer diagnosis Unemployed 18% 82%
Perceived Social Yes 94 78% 
Support No 26 22%
The prevalence of MDD in this study was 18% (21/120). However, the presence of MDD was only signifi cantly 
associated with the lack of perceived social support (χ² = 5.31, p = .021), presence of physical pain (χ² = 15.35, 
p < .001), presence of past psychiatric history (χ² = 6.22, p = .013), and poorer QOL, i.e. in physical health, 
psychological health, social relationships and environmental aspects (p < .001). Table 2, 3 and 4 summarize the 
prevalence of MDD and its associations with socio-demographic, clinical and other factors.
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Table 2.  MDD in gynaecological cancer patients in relation to socio-demographic factors
 
 Major Depressive Disorder
 (MDD)
 N = 120  
  No Yes χ² p value
Ethnic Malay 62 13 0.41 .814
 Chinese 23 5
 Indian 9 3 
Religion Islam 64 13 2.65 .450
 Buddhism 24 5
 Christianity 5 0
 Hinduism 6 3 
Religious practice Infrequent 20 5 0.14 .712
 Frequent 79 16
Marital status Married 66 17 1.66 .198
 Not married 33 4 
Education level Low 61 15 0.72 .397
 High 38 6
Quitting job after Yes 34 12 3.18 .074
cancer diagnosis No 21 1
Perceived Social Support Yes 12 82 5.31 .021*
 No 9 17
Husband helps in Yes 48 10 1.24 .265
household work No 18 7 
Presence of young Yes 32 6 0.37 .545
children at home No 54 14
Table 3.  MDD in gynaecological cancer patients in relation to clinical factors
 
 Major Depressive Disorder
 (MDD)
 N = 120  
  No Yes χ² p value
 Ovary  50 9 1.97 .741
 Endometrium  21 5  
 Cervix  26 6  
 Vagina  1 0  
 Vulva  1 1     
Stage of cancer Early (1)  35 6 0.35 .552
 Advanced (2-4)  64 15 
Metastasis Yes  25 6 0.10 .752
 No  74 15  
Recurrence Yes  20 5 0.005 .941
 No  79 16 
 Operation Yes 84 20 0.84 .358




Artkl 7.indd   56 26/11/2013   14:35:36
The Prevalence and Risk Factors of Major Depressive Disorders in Gynaecological Cancer Patients  57
Malaysian Journal of Medicine and Health Sciences Vol. 9 (2) June 2013
Table 4.  MDD in gynaecological cancer patients in relation to quality of life
PQOL domain Major Depressive  Mean rank Mann-Whitney U P value
 Disorder (MDD)
Physical health Yes 27.17 339.5 < .001*
 No 67.57 
Psychological health Yes 21.62 223.9 < .001*
 No 68.75 
Social relationship Yes 39.43 597.0 < .001*
 No 64.97 
Environment Yes 33.60 474.5 < .001* 
 No 66.21
Table 3.  Continued
 
 Major Depressive Disorder
 (MDD)
 N = 120  
  No Yes χ² p value
 Ongoing Yes 45 10 0.03 .857
 Chemotherapy No 54 11
 Completed Yes 40 6 1.03 .311
 Chemotherapy No 59 15
 Radiotherapy Yes 26 4 0.48 .488
  No 73 17
Physical pain  Yes  45 20 15.35 < .001*
 No   54 1
Concurrent medical Yes  50 11 0.02 .876
illness No  49 10
Concurrent medical Yes  52 10 0.17 .683
treatment No  47 11  
History of past Yes  7 6 6.21 .013
psychiatric illness No  92 15
Family history of Yes  11 2 0.00 1.000
psychiatric illness  No  88 9
Overall sexual Yes  41 13 1.22 .268
dysfunction  No  25 4
Other sexual  Yes  37 - 49 10 - 15 0 - 1.58 .21 – 1.0
dysfunction  No  17 - 25 2 - 7
domains**  
  
** Sexual desire, arousal, lubrication, orgasm, satisfaction, and pain
Treatment 
modalities
Age, ethnic, religion, religious practice, marital status, education level, employment status, whether husband 
helps in the household, presence of children below 18 years old or less at home, types, staging and duration of 
cancer, treatment modalities, presence of metastasis and recurrence, presence of medical illness and treatment, 
family history of psychiatric illness, and overall sexual dysfunction were not associated with MDD (p > 0.05).
Logistic regression analysis of the signifi cant variables (Table 5) showed that only the psychological health 
domain of QOL was signifi cantly associated with MDD (OR = 0.90, 95% CI = 0.84 – 0.98). About 60% of the 
variation in MDD was likely to be explained by its relationship with the psychological aspects of quality of life.
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DISCUSSION
The prevalence of MDD disorder among the gynaecological cancer patients in this study was 18%. This is more 
or less similar with the results found in other studies on gynaecological cancer patients: 13%[4], 12-23%[13], and 
23%[23]. The slight difference in the prevalence is probably caused by the differences in the sample size, types 
of questionnaires used, treatment factors, and the settings, where the studies were carried out. Meanwhile, the 
prevalence rate is generally higher than those in the primary care (6.7-14.4%) and general community (8.3 - 13.9%) 
in Malaysia[24]. In other words, about 1 in 5 of the patients had MDD, and that is excluding those with milder 
forms of depression (dysthymia and adjustment disorder with depressed mood). This is clinically very signifi cant 
in view that MDD can negatively infl uence the course of physical illness. In a three-year follow-up study on 
gynaecological patients, it was noted that those with MDD had more visits to healthcare personnel and utilization 
of phone counselling services[25]. Therefore, more psychosocial interventions, which have been shown to be useful 
[26], are highly recommended in gynae-oncology units.
The perceived lack of social support was signifi cantly associated with MDD. This fi nding is similar to the 
study on long-term gynaecological cancer survivors, whereby social support moderates the relationship between 
physical functioning and psychological outcomes[27]. Nonetheless, all these are not surprising as humans are 
basically social beings who need social support for their growth and development. During challenging periods in 
life (e.g., battling with cancer), emotional and family supports are even more crucial for reducing depression and 
psychological distress [28]. Family members and friends can give information, companionship, comfort and sense 
of security to cancer patients. These are crucial factors for buffering emotional distress, as well as preventing and 
treating MDD. As parts of psychosocial intervention, regular sessions with family members are recommended as 
these can help to facilitate social support and minimize family confl icts (misunderstanding and disagreement on 
treatment options) related to patient care.
The association between greater physical pain perception and MDD is also not surprising and has been shown 
in many other studies[3, 13]. Physical pain (either from cancer itself or the side effects of treatment) can precipitate 
and perpetuate MDD in cancer patients. On the other hand, depression can lower the threshold of physical pain 
perception and result in amplifi cation of pain experience[29]. In related to this, antidepressant treatment has been 
shown to reduce pain perception in cancer patients[30]. Therefore, it is important for us to remember that pain has 
several inter-related dimensions (e.g., biological and psychosocial). Recognising physical pain is relatively easier 
as compared to emotional pain (e.g. MDD). Therefore, the routine use of short and simple depression questionnaire, 
e.g., Patient Health Questionnaire – PHQ 9 (available in English, Malay and Chinese) may be helpful in recognising 
and addressing psychological pain, which in turn helps in physical pain management.
The presence of past psychiatry history was found to be signifi cantly associated with MDD, and this is also 
consistent with the fi nding of other studies[3, 13]. Patients who had suffered from depression, anxiety or other 
psychiatric problems at any time in the past are at risk of relapsing under the stress of having cancer. To some 
degree, having MDD and cancer is like having a ‘double cancer.’ MDD is not just a disease of the mind/brain; it 
is a ‘systemic disease’ with psychosomatic consequence. Besides, it also often disrupts family and interpersonal 
harmony – MDD does recur like cancer and ‘metastasize,’ compromising physical and social well-being. Thus, 
extra attention should be given to this subgroup of patients with ‘double cancer.’
All domains of quality of life were shown to be signifi cantly associated with MDD, and this is consistent with 
the study by Harrison et al.[17]. This is expected as MDD is known to be a disabling illness that interferes with 
Table 5. Logistic regression analysis of relationship between signifi cant variables and MDD   
 
Variable Coeffi cient Standard Wald p value Odds 95% 
 (β) Error χ²  Ratio CI
Perceived social support 0.23 0.95 0.06 .811 1.26 0.19 to 8.15      
Presence of physical pain 2.15 1.20 3.20 .074 8.60 0.81 to 90.97      
Past psychiatric history 1.34 0.97 1.91 .167 3.81 0.57 to 25.45      
QOL - Physical health -0.05 0.04 1.53 .217 0.96 0.89 to 1.03      
QOL - Psychological health -0.10 0.04 6.27 .012* 0.90 0.84 to 0.98      
QOL – Social relationship -0.01 0.03 0.15 .697 0.99 0.94 to 1.04      
QOL – Environmental aspect -0.08 0.05 1.99 .159 0.93 0.84 to 1.03
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quality of life. The observation was also confi rmed by logistic regression analysis, whereby the psychological health 
component of QOL stood out as the only factor that was associated with MDD. However, the different domains of 
sexual dysfunctions and the overall sexual dysfunction were not associated with MDD. Maybe when a potentially 
life threatening cancer strikes the patients, they would be less preoccupied with the issue of sexual dysfunction. 
Hence, surviving through cancer became the top priority issue as compared to those related to sexuality. They 
could also be so depressed and in emotional pain that sexual problem was relatively insignifi cant. 
It is also important to highlight that types, staging, duration, treatment modalities, presence of metastasis and 
recurrence of cancer were not associated with MDD. These observations are slightly different from some of those 
studies in existing literature. Some examples are given: 1. Women with breast and gynaecological cancer who 
received radiotherapy or chemotherapy (compared with surgery only), and had longer duration of cancer were 
more likely to maintain high anxiety and depressive symptoms over time[31], and 2. Patients with cervical cancer 
radiation treatment regimes were more likely to have depression[10]. However, a local study by Zainal also found 
that the primary site of cancer was not associated with psychological distress[8]. The difference in these fi ndings 
is probably contributed by the different research methodologies used and power of study.
This study has several limitations. First, non-probability sampling method was used, whereby data collection 
was done only on Mondays and Tuesdays (coincided with the follow-up clinics). Many new cases could have been 
missed as the new case clinics were on Thursdays. Second, the MINI diagnosis tool was not able to choose cases 
of adjustment disorder with depressed mood. Identifying this population is important as attention can be given 
to prevent them from progressing to having MDD. Third, recall bias could have affected information related to 
duration of cancer diagnosis, stage of cancer, treatment modalities, family history of psychiatric illness, etc. This 
can be overcome by checking clinical records and interviewing the carers or close family members. Fourth, the 
study did not include information on life events (non-cancer related), which is a plausible risk factor for depression. 
Finally, being a cross sectional study, only associative conclusions can be made, instead of causative ones.
CONCLUSION
The prevalence of Major Depressive Disorder (MDD) in gynaecological cancer patients at Hospital Sultanah 
Bahiyah, Alor Star was 18%. This fi gure is higher than those in the general population. The associated risk 
factors of MDD are lack of perceived social support, higher physical pain perception, presence of past psychiatric 
history, and poor quality of life. In view of the negative effects of MDD on cancer prognosis and patient’s well-
being, psychosocial intervention is highly recommended as a part of the multi-disciplinary and comprehensive 
management of gynaecological cancer.
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